Please assess the completion status of the following clinical trial:

Trial Title: Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has given written Informed Consent.~* Histologically confirmed, unresectable, metastatic diffuse gastric cancer including carcinoma of the gastro-esophageal junction.~* No prior chemotherapy for gastric cancer except adjuvant and/or neo-adjuvant chemotherapy more than 12 months ago.~* Life expectancy of at least 3 months.~* Able to take medications orally.~* Eastern Cooperative Oncology Group performance status 0 to 1.~* Adequate organ function (bone marrow, kidney and liver).~Exclusion Criteria:~* Certain type(s) of non-measurable lesion(s), if the only one(s).~* Certain serious illness or medical condition(s).~* Lost greater than or equal to 10% of body weight in the 3 months proceeding signing the Informed Consent Form.~* Treatment with drugs interacting with S-1, 5-FU, or cisplatin.~* Pregnant or lactating female.~* Known hypersensitivity to fluoropyrimidines or cisplatin.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1+Cisplatin (Type: EXPERIMENTAL): Participants received S-1 25 milligrams per meter square (mg/m\^2) orally twice daily (BID) every 12 hours from Day 1 through Day 21, 1 hour before or after meal with a glass of water; followed by a 7-day rest period from Day 22 to Day 28 in a 28-day cycle. Participants received a single dose of cisplatin 75 mg/m\^2 as a 1- to 3-hour intravenous (IV) infusion on Day 1 following the morning dose of S-1 for a maximum of 8 cycles (each cycle of 28 days). Participants received study medication until progression of disease (PD), adverse event (AE), withdrawal of consent, or other reason for discontinuation, whichever happened earlier.
- 5FU+Cisplatin (Type: ACTIVE_COMPARATOR): Participants received 5-Fluorouracil (5-FU) 800 mg/m\^2 per 24 hours as continuous IV infusion over 120 hours from Day 1 through Day 5 followed by a 16-day rest period on Days 6 through 21 in a 21-day cycle. Participants received a single dose of cisplatin 80 mg/m\^2 as a 1- to 3-hour IV infusion on Day 1 prior to the start of the 5-FU infusion on Day 1 for a maximum of 8 cycles (each cycle of 21 days). Participants received study medication until PD, AE, withdrawal of consent, or other reason for discontinuation, whichever happened earlier.

Based on this trial design, predict the completion outcome and termination type (if applicable).